drugset / Trial / NCT00887770

A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart

NCT00887770

Phase 1 Completed 64 enrolled AstraZeneca Quintiles, Inc. · collab
RandomizedCrossoverTriple-blindBasic science

Summary

This study is being performed to investigate the potential for AZD5672 to affect the electrical conduction pathways in the heart. AZD5672 will be compared against a drug (moxifloxacin - a licensed antibiotic) known to have a detectable but safe change on the electrical conduction of the heart.

Timeline

Start
2009-04
Primary completion
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5672 Small molecule 150 mg Oral
Subject AZD5672 Small molecule 600 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral

Indications